Obstacles to early treatment of idiopathic pulmonary fibrosis: current perspectives
Teng Moua, Jay H Ryu Department of Medicine, Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester MN, USA Abstract: Idiopathic pulmonary fibrosis is a progressive and fatal fibrotic lung disease which has seen new opportunity for drug treatment in the last several year...
Main Authors: | Moua T, Ryu JH |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2019-01-01
|
Series: | Therapeutics and Clinical Risk Management |
Subjects: | |
Online Access: | https://www.dovepress.com/obstacles-to-early-treatment-of-idiopathic-pulmonary-fibrosis-current--peer-reviewed-article-TCRM |
Similar Items
-
South–West of England’s Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
by: Shaney L. Barratt, et al.
Published: (2018-12-01) -
Pharmacological treatment of idiopathic pulmonary fibrosis and fibrosing interstitial lung diseases: current trends and future directions
by: Won-Il Choi
Published: (2021-03-01) -
Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis
by: Gareth Hughes, et al.
Published: (2016-09-01) -
Idiopathic pulmonary fibrosis: pathogenesis, progression, treatments, and future prospects
by: Ouchi, Hideyasu
Published: (2019) -
Idiopathic Pulmonary Fibrosis (IPF): An Overview
by: Shaney L. Barratt, et al.
Published: (2018-08-01)